A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study

EMBER-2 combined with existing phase I data has identified 400 mg as the optimal imlunestrant dose.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2024-10-08
DOI
https://doi.org/10.1158/1078-0432.ccr-24-2113
Citations
6
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
1.70

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study

Erika Hamilton, María Vidal, François‐Clément Bidard, Patrick Neven et al.
6 citations
Clinical Cancer Research
HER2/EGFR in Cancer Research
1.70
article

A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study

Erika Hamilton, María Vidal, François‐Clément Bidard, Patrick Neven, Peter A. Kaufman, Roohi Ismail‐Khan, Bastien Nguyen, Kelly K. Hunt, Peter A. Fasching, Manali Bhave, Nadia Harbeck, Duncan Wheatley, Nicole Stahl, Umut Özbek, Shawn T. Estrem, Rebecca Aft, Claudia Karacsonyi, Peter Schmid, Eunice Yuen, Eva Ciruelos, Philippe Aftimos, Swati Kulkarni, Miguel Martín, Stacey Carter, Vanessa Rodrik-Outmezguine
article en
6 citations

Abstract

EMBER-2 combined with existing phase I data has identified 400 mg as the optimal imlunestrant dose.

Clinical Cancer ResearchVol. 30(23)
University of Vermont (US), Northwestern University (US), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), Emory University (US), Queen Mary University of London (GB), Eli Lilly (United States) (US), Baylor College of Medicine (US), Breast Cancer Research Foundation (US), Washington University in St. Louis (US), Royal Cornwall Hospital Trust (GB), Royal Cornwall Hospital (GB), Universitair Ziekenhuis Leuven (BE), Institut Jules Bordet (BE), Hospital General Universitario Gregorio Marañón (ES), Research Institute Hospital 12 de Octubre (ES), Piedmont Cancer Institute (US), Sarah Cannon (US), Helios Hospital Schwerin (DE), Hospital Universitario 12 De Octubre (ES), HM Hospitales (ES), Tennessee Oncology (US), Vermont Cancer Support Network (US), Comprehensive Cancer Center Erlangen (DE), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), GEICAM – Spanish Breast Cancer Group (ES), Universitat de Barcelona (ES), Institut Curie (FR), Ludwig-Maximilians-Universität München (DE)
Eli Lilly and Company
Good health and well-being
Openalex Percentile: Top 13%
HER2/EGFR in Cancer Research
1.70
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.